fms Like Tyrosine kinase3- Internal Tandem Duplication (FLT3-ITD) in Acute Myeloid Leukemia, Mutation Frequency and its Relation with Complete Remission, 2007- 2008
-
Amir Hossein Emami
,
Ramin Shekarriz
,
A Meysamie
,
Ramazanali Sharifian
,
R Safaei
,
Ghlamreza Toogheh
,
Manouchehr Keihani
,
R Shekarriz
Abstract
Introduction: About half of acute myeloid leukemia (AML) adult patients have no cytogenetic abnormalities as a main determinant of complete remission after treatment, so other markers are needed such as FLT3-ITD (Fms-like Tyrosine kinase3-internal tandem duplication) mutations in patients with normal karyotype. The objective of this study was assessing the frequency of FLT3-ITD mutations and its relation with complete remission in different FAB (French- American- British) and cytogenetic subgroups of AML patients who had been hospitalized at Tehran Imam Khomeini Hospital, hematology ward.
Methods: The current study, was a cross sectional descriptive study which was performed during the years 2007-2008. Population frame were consecutive patients whose diseases were confirmed and who had been hospitalizedin Tehran Imam Khomeini Hospital, hematology ward. Contemporary, flowcytometry, cytogenetic and chromosomal studies were performed for the cytogenetic subgroup assessment and to investigate the presence of FLT3-ITD mutation. Finally, complete remission achievement after induction chemotherapy were assessed. The obtained data was entered onto the information forms and analyzed by statistical tests.
Results: Out of 40 patients who participated in this study, 18 (45%) were female and 22 (55%) were male. The median age of the patients with mutation was 33 years of age, and the ones without mutation were 39.5. M1, M2and M4 FAB subgroups, with respectively 60, 37.5 and 35.7%, had the most occurrence of mutation. There was no significant relationship between mutation and the FAB subgroups (P=0.45). Favorable, intermediate and adverse cytogenetic risk groups had respectively 10, 37 and 66.7% mutations and 69.2% of the patients were in the normal karyotype group. Seventeen (42.5%) of the 40 patients achieved complete remission. 17.6% of them had mutations. There was no relationship between mutation and complete remission (P=0.085).
Conclusion: There was no relationship between thepresence ofFLT3-ITD mutation and complete remission achievement following chemotherapy.
Steudel C, Wernke M. Comparative Analysis of MLL Partial Tandem Duplication and FLT-3 Internal Tandem Duplications in 956 Adult Patients with AML. GENES, CHROMOSOMES & CANCER, 2003; 37: 237- 251.
Grimwade D, Walker H, Oliver F, et al. The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1612 Patient Entered into the MRC AML 10 Trial. Blood, 1998; 92: 2322-33.
Suciu S, Mandelli F, De witte T, et al. Allogenic Compared with Autologous Stem Cell Transplantation in the Treatment of Patient Younger than 46 Years with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1): An Intention- to- Treat Analysis of the EORTC/GIMEMA AML- 10 Trial. Blood, 2003; 102: 1232- 40.
Slovak ML, Kopecky Ky, Casssileth PA, et al. Karyotypic Analysis Predicts Outcome of Preremission and Postremission Therapy in Adult Acute Myeloid Leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood, 2000; 96: 4075- 83.
Dina Yassin, Iman Sidhom. Internal Tandem Duplication of FLT3 Gene in Egyptian Pediatric Acute Myeloid leukemia and Acute Lymphoblastic Leukemia. Journal of the Egyptian Nat. Cancer Ins. 2000; 15 (1): 7-23.
Levis M, Smell D: FLT3: It does Matter in Leukemia. Leukemia, 2003; 17 (9): 1738- 52.
Gilliland DG, Griffin JD: The Roles of FLT3 in Hematopoiesis and Leukemia. Blood 2002; 100(5): 1532-42.
Kottaridis PD, Gale RE, et al. The Presence of a FLT3 Internal Tandem Duplication with AML Adds Important Prognostic to the First Cycle of Chemotherapy: Analysis of 854 Patients from the UKMRC AML 10 and 12 Trials. Blood, 2001; 98(6): 1752-9.
Yanada M, Matsuo K, Suzuki T. Prognostic Significance of FLT3 Internal Tandem Duplication and Tyrosine Kinase Domain Mutations for Acute Myeloid Leukemia: A Meta- analysis. Leukemia, 2005; 19(8): 1345-9.
Wang L, Lin D, Zhang X, et al: Analysis of FLT3 Internal Tandem Duplication and D835 Mutations in Chinese Acute Leukemia Patients. Leuk Res, 2005; 29(12): 1393-8.
Brown P, Meshinchi S, Levis M, et al. Pediatric AML Primary Samples with FLT3-ITD Mutations are Preferentially Killed by FLT3 Inhibition. Blood, 2004; 104: 1841- 1849.
Knapper S, Mills KJ, Gilkes AF, et al. The Effects of Lestauritinib (CEP701) and PKC412 ON Primary AML Blasts: The Induction of Cytotoxicity Varies with Dependence on FLT3 Signaling in both FLT3- mutated and Wild- type Cases. Blood, 2006; 108: 3494-3503.
Meshinchi S, Arceci RJ, Sanders JE, et al. Role of Allogenic Stem Cell Transplantation in FLT3/ITD– Positive AML. Blood, 2006; 108: 400.
Bornhauser M, Illmer T, Schaich M, et al. Improved Outcome after Stem Cell Transplantation in FLT3- ITD- positive AML. Blood, 2007; 2264- 2265.
Frohling S, Schlenk RF, Breitruck J, et al. Prognosic Significance of Activating FLT3 Mutations in Younger Adults with Acute Myeloid Leukemia and Normal Cytogenetics: A Study of the AML Study Group ULM. Blood, 2002; 100: 4372- 4380.
Bienz M, Ludwig M, Leibundgut EO,et al. Risk assessment in patient with AML and a normal Karyotype . Clinical Cancer Res, 2005; 11: 1416- 1424.
Mills KI, Gilkes AF, Walsh V. Rapid and Sensitive Detection of Internal Tandem Duplication and Activating Loop Mutations of FLT3. Br J Haematol, 2005; 130(2):203-8.
Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 Length Mutations in 1003 Patients with AML: Correlation to Cytogenetics, FAB Subtype, and Prognosis in the AMLCG Study and Usefulness as a Marker for the Detection of Minimal Residual Disease. Blood, 2002; (100): 59- 66.
Van Waalwijk B, van Doorn-Khosorvani S, Erpelinck C, et al. Biallelic Mutations in the CEBPA Gene and Low CEBPA Expression Levels as Prognostic Markers in Intermediate- Risk AML. Hematol J, 2003; 31-40.
Baldus CD, Tanner SM, Ruppert AS, et al. BAALC Expression Predicts Clinical Outcome of de novo Acute Myeloid Leukemia Patients with Normal Cytogenetics: A Cancer and Leukemia Group B Study. Blood, 2003; 102: 1613- 8.
Schlenk RF, Döhner K, Krauter J, et al. Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia. N Engl J Med, 2008; 358: 1909-18.
| Files | ||
| Issue | Vol 3, No 4 (2009) | |
| Section | Articles | |
| Keywords | ||
| Acute Myeloid Leukemia FLT3-ITD Mutation FAB Subgroups Cytogenetic Risk Groups | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
